Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Non Operating Income (2016 - 2025)

KalVista Pharmaceuticals' Non Operating Income history spans 10 years, with the latest figure at $2.4 million for Q2 2025.

  • For Q2 2025, Non Operating Income rose 1174.12% year-over-year to $2.4 million; the TTM value through Apr 2025 reached $5.9 million, down 30.4%, while the annual FY2025 figure was $4.8 million, 50.73% down from the prior year.
  • Non Operating Income for Q2 2025 was $2.4 million at KalVista Pharmaceuticals, up from $2.1 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $3.8 million in Q3 2023 and bottomed at -$228000.0 in Q2 2024.
  • The 3-year median for Non Operating Income is $2.3 million (2024), against an average of $2.1 million.
  • The largest annual shift saw Non Operating Income plummeted 58.53% in 2024 before it soared 1174.12% in 2025.
  • A 3-year view of Non Operating Income shows it stood at $2.6 million in 2023, then dropped by 19.09% to $2.1 million in 2024, then increased by 15.57% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for KALV's Non Operating Income are $2.4 million (Q2 2025), $2.1 million (Q4 2024), and $1.6 million (Q3 2024).